Cell Genomics:肺腺癌肿瘤内异质性模式与肺癌患者生存率的关系

2022-08-25 MedSci原创 MedSci原创

最近研究人员采用蛋白质组学和基因组学方法来梳理肺腺癌患者的肿瘤组织内异质性表现模式与患者生存期的关系。

最近研究人员采用蛋白质组学和基因组学方法来梳理肺腺癌患者的肿瘤组织内异质性表现模式与患者生存期的关系。

肺腺癌的异质性是肿瘤医生普遍的认知,所谓异质性就是肿瘤组织中各类细胞的性质与分布比例,以及肿瘤微环境的构架存在不同。肿瘤内的异质性被认为与治疗的失败和耐药性的产生有关。但对肿瘤内异质性的认识尚不深入。Dana-Farber癌症研究所的科研人员利用多区域质谱,单细胞测序和循环免疫荧光技术,对肺腺癌的肿瘤内异质性进行了检测和研究。

研究发现,肿瘤内结构中多种类型细胞的分布,存在着两种不同的空间模式,一种被称之为聚簇型分布模式(clustered),另一种为随机区域多样化(random geographic diversification)分布模式。进一步的分析发现随机区域多样化模式与细胞粘附性下降和患者存活率下降相关。

屏幕截图2 2022-08-20 140804.png

分析研究结果提供一个全面的数据集,显示了单个组织切片中数十个区域的空间肿瘤内蛋白质组异质性程度的差异,也显示了肿瘤内浸润性免疫细胞的空间分布模式的不同,并表明肺腺癌的肿瘤内空间中单个肿瘤细胞基因组也存在的异质性。针对患者的标本切片,研究使用一种新颖的分析方法,检查标本中蛋白质组的区域空间分布多样化,并侧重于分析分子特征与肿瘤内区域位置分布之间的联系。采用上述检测技术(蛋白质和基因组分布)和分析方法,可以将患者肿瘤内细胞的分布空间模式分为两类:聚簇型(Clustered)和随机区域多样化型(Random)(图1)。而肿瘤内呈现为随机区域多样化分型的患者死亡风险增加。

演示文稿3.jpg

     通过对53例肿瘤标本进行额外的批量RNA测序,发现某些转录标志在不同的随机区域多样化型病例中活跃性差。例如:在Random样本中,细胞-细胞粘附相关途径中(钙粘蛋白结合,跨膜转运和细胞外基质基因等)中的基因表达降低。这些转录程序的表达减少可能导致细胞-细胞之间粘附力减少,能促进癌细胞的迁移和入侵能力,并可能导致Random模式的进一步扩张。

     研究还使用循环免疫荧光方法,对数十几名患者的FFPE(福尔馬林固定石腊包埋)肿瘤病理组织中的1000多万细胞进行了检测,来分析肿瘤内的细胞组成。尽管研究发现基于蛋白质组学检查的Random模式与基于免疫细胞浸润区域多样化分型之间并没有相关性。但研究显示,肿瘤内聚簇型细胞分布总体上具有较高的肿瘤细胞含量。研究还发现某些肿瘤内聚簇中的肿瘤细胞多来自同一区域的单个细胞,它们倾向于聚集在一起,享有共同的祖先细胞来源,表现为聚簇型分布的特点;而另一些肿瘤标本中没有检测出这种聚簇型细胞分布的存在,表现为Random多样化模式。研究确认了肿瘤组织内Clustered和Random两种空间分布模式,是可以通过蛋白质组学和基因组学技术来分析检测的。推测这种深层次的(higher-order tumor structural features)的肿瘤内异质性,也可以用作新型肿瘤生物标志物。这一策略将为组织切片中的预后性生物标志物的未来发展提供新的见解。

Figure1.jpg

原始出处:

Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients,Vol 2:8, 10 August 2022  Cell Genomices

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932728, encodeId=e7261932e28b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Apr 05 08:06:16 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990801, encodeId=7e671990801e4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Mar 20 06:06:16 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872511, encodeId=b89f18e2511ac, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 25 05:06:16 CST 2023, time=2023-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962841, encodeId=5d6a19628412e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 05 11:06:16 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077819, encodeId=5c5f20e781982, content=<a href='/topic/show?id=6f8ee950ba' target=_blank style='color:#2F92EE;'>#genomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7950, encryptionId=6f8ee950ba, topicName=genomics)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 24 15:06:16 CST 2022, time=2022-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256918, encodeId=c33b12569186d, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Aug 27 00:06:16 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240867, encodeId=a397124086e07, content=收获满满, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05648246800, createdName=ms9000001565619739, createdTime=Thu Aug 25 09:16:39 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932728, encodeId=e7261932e28b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Apr 05 08:06:16 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990801, encodeId=7e671990801e4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Mar 20 06:06:16 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872511, encodeId=b89f18e2511ac, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 25 05:06:16 CST 2023, time=2023-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962841, encodeId=5d6a19628412e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 05 11:06:16 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077819, encodeId=5c5f20e781982, content=<a href='/topic/show?id=6f8ee950ba' target=_blank style='color:#2F92EE;'>#genomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7950, encryptionId=6f8ee950ba, topicName=genomics)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 24 15:06:16 CST 2022, time=2022-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256918, encodeId=c33b12569186d, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Aug 27 00:06:16 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240867, encodeId=a397124086e07, content=收获满满, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05648246800, createdName=ms9000001565619739, createdTime=Thu Aug 25 09:16:39 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932728, encodeId=e7261932e28b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Apr 05 08:06:16 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990801, encodeId=7e671990801e4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Mar 20 06:06:16 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872511, encodeId=b89f18e2511ac, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 25 05:06:16 CST 2023, time=2023-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962841, encodeId=5d6a19628412e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 05 11:06:16 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077819, encodeId=5c5f20e781982, content=<a href='/topic/show?id=6f8ee950ba' target=_blank style='color:#2F92EE;'>#genomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7950, encryptionId=6f8ee950ba, topicName=genomics)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 24 15:06:16 CST 2022, time=2022-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256918, encodeId=c33b12569186d, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Aug 27 00:06:16 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240867, encodeId=a397124086e07, content=收获满满, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05648246800, createdName=ms9000001565619739, createdTime=Thu Aug 25 09:16:39 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1932728, encodeId=e7261932e28b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Apr 05 08:06:16 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990801, encodeId=7e671990801e4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Mar 20 06:06:16 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872511, encodeId=b89f18e2511ac, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 25 05:06:16 CST 2023, time=2023-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962841, encodeId=5d6a19628412e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 05 11:06:16 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077819, encodeId=5c5f20e781982, content=<a href='/topic/show?id=6f8ee950ba' target=_blank style='color:#2F92EE;'>#genomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7950, encryptionId=6f8ee950ba, topicName=genomics)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 24 15:06:16 CST 2022, time=2022-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256918, encodeId=c33b12569186d, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Aug 27 00:06:16 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240867, encodeId=a397124086e07, content=收获满满, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05648246800, createdName=ms9000001565619739, createdTime=Thu Aug 25 09:16:39 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-12-05 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1932728, encodeId=e7261932e28b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Apr 05 08:06:16 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990801, encodeId=7e671990801e4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Mar 20 06:06:16 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872511, encodeId=b89f18e2511ac, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 25 05:06:16 CST 2023, time=2023-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962841, encodeId=5d6a19628412e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 05 11:06:16 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077819, encodeId=5c5f20e781982, content=<a href='/topic/show?id=6f8ee950ba' target=_blank style='color:#2F92EE;'>#genomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7950, encryptionId=6f8ee950ba, topicName=genomics)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 24 15:06:16 CST 2022, time=2022-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256918, encodeId=c33b12569186d, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Aug 27 00:06:16 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240867, encodeId=a397124086e07, content=收获满满, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05648246800, createdName=ms9000001565619739, createdTime=Thu Aug 25 09:16:39 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1932728, encodeId=e7261932e28b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Apr 05 08:06:16 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990801, encodeId=7e671990801e4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Mar 20 06:06:16 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872511, encodeId=b89f18e2511ac, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 25 05:06:16 CST 2023, time=2023-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962841, encodeId=5d6a19628412e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 05 11:06:16 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077819, encodeId=5c5f20e781982, content=<a href='/topic/show?id=6f8ee950ba' target=_blank style='color:#2F92EE;'>#genomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7950, encryptionId=6f8ee950ba, topicName=genomics)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 24 15:06:16 CST 2022, time=2022-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256918, encodeId=c33b12569186d, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Aug 27 00:06:16 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240867, encodeId=a397124086e07, content=收获满满, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05648246800, createdName=ms9000001565619739, createdTime=Thu Aug 25 09:16:39 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1932728, encodeId=e7261932e28b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Apr 05 08:06:16 CST 2023, time=2023-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990801, encodeId=7e671990801e4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Mar 20 06:06:16 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872511, encodeId=b89f18e2511ac, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 25 05:06:16 CST 2023, time=2023-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962841, encodeId=5d6a19628412e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 05 11:06:16 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077819, encodeId=5c5f20e781982, content=<a href='/topic/show?id=6f8ee950ba' target=_blank style='color:#2F92EE;'>#genomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7950, encryptionId=6f8ee950ba, topicName=genomics)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 24 15:06:16 CST 2022, time=2022-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256918, encodeId=c33b12569186d, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Aug 27 00:06:16 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240867, encodeId=a397124086e07, content=收获满满, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05648246800, createdName=ms9000001565619739, createdTime=Thu Aug 25 09:16:39 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-08-25 ms9000001565619739

    收获满满

    0

相关资讯

Nat Commun:免疫疗法效力不足?瘤内异质性或为关键!

导 读:肝癌是全球第四大致死性癌症,在我国恶性肿瘤发病率中肝癌位列第四。来自两项使用PD-1抑制剂的2期临床试验结果表明,约18%的肝癌患者显著受益于免疫检查点抑制剂,这提示我们进一步了解肝癌与免疫相互作用可以更好地帮助识别新型肿瘤标志物,助力临床诊断。